1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. FibroGen, Inc.
  6. Summary
    FGEN   US31572Q8087

FIBROGEN, INC.

(FGEN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 05/26 01:05:58 pm
9.235 USD   +6.64%
07:01aFibroGen to Present at Jefferies Healthcare Conference
AQ
05/24Goldman Sachs Adjusts FibroGen's Price Target to $8 from $9, Keeps Sell Rating
MT
05/10Top Midday Gainers
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/26/2022 Date
8.6(c) 8.75(c) 8.52(c) 8.66(c) 9.19 Last
895 298 828 429 2 196 722 2 171 428 570 327 Volume
+0.35% +1.74% -2.63% +1.64% +6.12% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 185 M - -
Net income 2022 -334 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,53x
Yield 2022 -
Sales 2023 244 M - -
Net income 2023 -223 M - -
Net Debt 2023 - - -
P/E ratio 2023 -3,89x
Yield 2023 -
Capitalization 808 M 808 M -
Capi. / Sales 2022 4,37x
Capi. / Sales 2023 3,31x
Nbr of Employees 566
Free-Float 92,0%
More Financials
Company
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of therapeutics. It applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral... 
More about the company
Ratings of FibroGen, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about FIBROGEN, INC.
07:01aFibroGen to Present at Jefferies Healthcare Conference
AQ
05/24Goldman Sachs Adjusts FibroGen's Price Target to $8 from $9, Keeps Sell Rating
MT
05/10Top Midday Gainers
MT
05/09FIBROGEN INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
05/09TRANSCRIPT : FibroGen, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09FIBROGEN : Q1 Earnings Snapshot
AQ
05/09FibroGen Q1 Loss Narrows, Revenue Rises
MT
05/09Earnings Flash (FGEN) FIBROGEN Reports Q1 Revenue $60.8M, vs. Street Est of $28.8M
MT
05/09Earnings Flash (FGEN) FIBROGEN Reports Q1 Loss $-0.68, vs. Street Est of $-0.92
MT
05/09FibroGen Reports First Quarter 2022 Financial Results
AQ
05/09FibroGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Blockbuster Blood Thinning Patent Revoked
AQ
04/25FibroGen to Report First Quarter 2022 Financial Results
AQ
04/20FibroGen Completes Enrollment for Zephyrus-1 Trial
MT
04/20FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical S..
AQ
More news
News in other languages on FIBROGEN, INC.
05/09La perte de FibroGen au premier trimestre diminue, les revenus augmentent
05/09Earnings Flash (FGEN) FIBROGEN annonce un chiffre d'affaires de 60,8 millions de dollar..
05/09FibroGen, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/20FibroGen, Inc. Annonce la fin du recrutement des patients dans ZEPHYRUS-1, une étude cl..
02/28La perte nette par action de FibroGen au quatrième trimestre s'accentue, les recettes d..
More news
Analyst Recommendations on FIBROGEN, INC.
More recommendations
Chart FIBROGEN, INC.
Duration : Period :
FibroGen, Inc. Technical Analysis Chart | FGEN | US31572Q8087 | MarketScreener
Technical analysis trends FIBROGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 8,66 $
Average target price 13,20 $
Spread / Average Target 52,4%
EPS Revisions
Managers and Directors
Enrique A. Conterno Chief Executive Officer & Director
Juan Graham Chief Financial Officer & Senior Vice President
James A. Schoeneck Chairman
Michael Martinelli Senior Vice President-Technical Development
Elias Kouchakji Senior VP-Clinical Development & Drug Safety
Sector and Competitors
1st jan.Capi. (M$)
FIBROGEN, INC.-38.58%808
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232